An early-stage GW Pharmaceuticals.

• SCI-110 (Dronabinol/Palmitoylethanolamide): A proprietary cannabinoid-based drug candidate in clinical development for neurological and neuropsychiatric disorders such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder.
• SCI-160: A proprietary drug candidate being developed for the treatment of various conditions, including pain, inflammation, and irritable bowel syndrome.
• SCI-210: A proprietary drug candidate in development targeting the treatment of status epilepticus.

SciSparc (SPRC) is a clinical-stage pharmaceutical company focused on the development of cannabinoid-based therapies. However, it also holds a majority stake in Point of View Ltd. (POV), which operates the "Wellution" brand. While its pharmaceutical pipeline involves a B2B model for potential future licensing or sales to healthcare systems, its current direct sales revenue and identifiable customer base primarily stem from the Wellution brand's direct-to-consumer sales.

Therefore, SciSparc primarily sells to individuals through its Wellution brand. The categories of customers it serves include:

• Health and Wellness Enthusiasts: Individuals actively seeking natural remedies, supplements, and CBD products to support general health, vitality, and proactive well-being.
• Consumers Seeking Symptom Relief: Customers looking for over-the-counter and natural options to address specific concerns such as sleep issues, stress, anxiety, or minor aches and pains, for which Wellution's products are marketed.
• Online Shoppers: Individuals who prefer the convenience of purchasing health and wellness products through e-commerce platforms like Amazon and the brand's direct website.

null

Oz Adler, Chief Executive Officer & Chief Financial Officer

Mr. Adler joined SciSparc in September 2017, became Chief Financial Officer in April 2018, and has served as Chief Executive Officer since January 2022. Prior to joining the company, he was a Certified Public Accountant at Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global. Mr. Adler currently chairs and serves as a director on the boards of several private and public companies, including Fort Technology Inc., Jeffs Brands Ltd., Rail Vision Ltd., Clearmind Medicine Inc., Polyrizon Ltd., and Charging Robotics Ltd. He previously served as Chief Financial Officer of Xylo Technologies Ltd. Charging Robotics Ltd., where Mr. Adler was a director, was acquired from Xylo Technologies Ltd. for $98.78 million in April 2023.

Amitay Weiss, President

Mr. Weiss was appointed President in September 2025. He previously served as SciSparc's Chief Executive Officer between August 2020 and January 2021 and has been on its Board of Directors since August 2020. Mr. Weiss is the founder and Chief Executive Officer of Amitay Weiss Management Ltd. Before forming his own company, he held various positions at Bank Poalei Agudat Israel Ltd., most recently as Vice President of Business Marketing & Development. He also chairs and serves as a director on the boards of several public companies.

Itschak Shrem, Chairman of the Board

Mr. Shrem was appointed Chairman of the Board in September 2025 and also served as President since January 2022. He brings over 40 years of experience in financial markets and venture capital. In 1991, Mr. Shrem founded Dovrat Shrem Ltd., an investment banking, management, and technology company. He also co-founded Pitango Venture Capital Fund (formerly Polaris) in 1993 and served as a partner. He spent 15 years at Clal Israel Ltd., where he served in various capacities including Chief Operating Officer. Since 1995, he has been the Managing Director of Yaad Consulting 1995 Ltd. Mr. Shrem has served on the board of directors of companies such as Rail Visions Ltd., Tel-Aviv Sourasky Medical Center, Weizman Institute Eden Spring Ltd., Nano Dimension Ltd., Ormat Industries Ltd., Retalix Ltd. and as Chairman of Sphera Funds Management Ltd.

Adi Zuloff-Shani, PhD, Chief Technologies Officer

Dr. Zuloff-Shani joined SciSparc in February 2016. She has more than 20 years of experience as a research and development executive in the bio-tech industry and in launching healthcare start-ups. She has successfully brought two products from bench to market. Prior to SciSparc, Dr. Zuloff-Shani served as Vice President Development at Macrocure Ltd.

The increasing global legalization, decriminalization, and societal acceptance of cannabis and non-prescription cannabinoid products (such as CBD and THC formulations) for medical and recreational use represent a clear emerging threat. As these products become more widely available, accessible, and often cheaper through retail and online channels, patients suffering from conditions that SciSparc targets (e.g., Tourette syndrome, autism, pain) may increasingly opt for these readily available alternatives to self-treat. This trend could significantly erode the potential market demand and uptake for SciSparc's rigorously tested, regulated, and typically more expensive prescription cannabinoid-based pharmaceutical drugs, thereby challenging their ability to achieve market penetration and profitability. This parallels how more accessible, often cheaper alternatives have disrupted traditional industries, such as streaming services impacting physical media rentals.

SciSparc (SPRC) is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders. The addressable markets for their main products and services are as follows:

• Tourette Syndrome: The global Tourette Syndrome treatment market was valued at approximately USD 2.07 billion in 2022 and is projected to reach USD 3.48 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 6.96% from 2023 to 2030. North America held the largest share of this market in 2024.
• Alzheimer's Disease and Agitation: The global market for the clinical treatment of agitation in Alzheimer's disease was valued at approximately USD 3.6 billion in 2023 and is projected to reach USD 8.2 billion by 2033, with a CAGR of 8.7%. North America dominates this market, accounting for over 45% of the global share. Another report indicates the market for agitation in Alzheimer's disease was USD 4.9 billion in 2024 and is projected to reach USD 8.6 billion by 2034 globally.
• Chronic Pain (Cannabinoid-based solutions): The global cannabinoid-derived pharmaceutical market size was valued at USD 12.6 billion in 2024 and is predicted to reach USD 81.1 billion by 2034, with a 20.8% CAGR. The broader global cannabis pharmaceuticals market was valued at approximately USD 3.17 billion in 2024 and is projected to reach USD 34.92 billion by 2034, exhibiting a CAGR of roughly 24.5% between 2025 and 2034. Chronic pain is the largest application segment for medical cannabis, holding 36.0% of the market share in 2023 globally.
• Obstructive Sleep Apnea (OSA): The 7 major obstructive sleep apnea markets (which typically include the U.S., Germany, France, Italy, Spain, UK, and Japan) reached a value of USD 794.9 million in 2024 and are expected to reach USD 4,066.7 million by 2035, exhibiting a growth rate (CAGR) of 16.2% during 2025-2035. The global sleep apnea devices market was estimated at USD 4.5 billion in 2023 and is projected to reach USD 6.9 billion by 2030. North America held a 48.1% share of the sleep apnea devices market in 2023.
• Autism Spectrum Disorder (ASD) and Status Epilepticus: Information on the specific addressable market sizes for SciSparc's products in Autism Spectrum Disorder and Status Epilepticus was not readily available in the provided search results.

1. Advancement and Potential Commercialization of Clinical-Stage Pharmaceutical Pipeline: SciSparc's primary focus remains on developing its portfolio of cannabinoid pharmaceuticals. Key drug candidates, such as SCI-110 for Tourette Syndrome and Alzheimer's disease and agitation, SCI-160 for pain, and SCI-210 for Autism Spectrum Disorder (ASD) and status epilepticus, are in various stages of clinical trials, including a Phase IIb clinical trial for SCI-110 for Tourette Syndrome. Successful progression through these trials and eventual market approval and sales would be a significant revenue driver.
2. Growth in Sales of Hemp-Based Products and Nutraceuticals: SciSparc currently generates revenue through the online sale of hemp seed oil-based products, including beauty and health supplements, primarily via the Amazon.com Marketplace. This existing segment, which is part of the assets intended for a spin-off into a new entity where SciSparc would retain a controlling interest, represents a current revenue stream with potential for expansion through increased customer acquisition and market penetration.
3. Strategic Partnerships and Licensing Agreements for Pharmaceutical Assets: The company's ongoing efforts to secure patents and engage in collaborations, such as the past collaboration with Clearmind on patent applications for various disorders, could lead to future strategic partnerships or licensing agreements for its drug candidates or intellectual property. Such agreements could generate upfront payments, milestone payments, and/or royalty revenues, contributing to growth.

Share Issuance

• SciSparc issued 61.21 million shares for resale by selling shareholders in March 2025, comprising 53.62 million shares from the conversion of $4.2 million in convertible debentures and 7.59 million shares from warrants.
• A 1-for-21 reverse share split became effective on July 3, 2025, reducing the number of outstanding ordinary shares from approximately 11.2 million to 534,600.
• The company effected a 140:1 reverse stock split in August 2021.

Inbound Investments

• SciSparc maintained a cash position of $1.5 million and working capital of $6.1 million as of December 31, 2024.
• The company received a $411,000 cash payment in February 2025 as part of a favorable lawsuit settlement.
• A merger agreement with AutoMax Motors, signed in April 2024 and extended to September 2025, included bridge loans totaling $6.25 million.

Outbound Investments

• In October 2025, SciSparc closed the acquisition of a publicly traded TSXV company, NeuroThera Labs Inc. (formerly Miza III Ventures Inc.), transferring its advanced clinical-stage pharmaceutical portfolio and a 51% stake in SciSparc Nutraceuticals Inc. The transferred assets were valued at approximately US$11.6 million.
• SciSparc is expected to hold a controlling interest of approximately 75% to 84% in NeuroThera Labs Inc., receiving 63.3 million common shares and up to 48 million contingent rights.
• SciSparc intends to commit up to CAD 1,000,000 (approximately $716,000) to NeuroThera Labs Inc. through a two-year unsecured convertible note and will receive 4 million common share purchase warrants.

Capital Expenditures

• Capital expenditures, as reflected in Property, Plant & Equipment, were consistently low, with values of $0.06 million in FY 2024, $0.11 million in FY 2023, $0.06 million in FY 2022, $0.09 million in FY 2021, and $0.01 million in FY 2020.
• SciSparc launched a quantum computing initiative in September 2025 to advance 3D protein modeling for drug discovery.